One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Geron Corporation logo
Geron Corporation GERN
$ 0.99 4.21%
report update icon

Quarterly report 2026-Q3
added 11-04-2026

Geron Corporation Financial Ratios 2025-2008 | GERN

Annual Financial Ratios Geron Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
-12.7 -5.9 -6.1 -7.2 -3.4 -5.7 -3.6 -6.7 -14.4 -10.4 10478.5 -13.7 -16.9 -2.6 -2.4 -4.4 - -

P/S

- - 4719.3 1712.3 286.9 1706.0 537.4 170.5 378.3 49.8 13.3 423.5 506.0 65.6 95.6 137.7 - -

EPS

-0.1 -0.3 -0.3 -0.4 -0.3 -0.3 -0.4 -0.1 -0.2 -0.2 - -0.2 -0.3 -0.5 -0.8 -1.1 -0.8 -

EV (Enterprise Value)

1.33 B 1.26 B 1.19 B 1.07 B 464 M 481 M 264 M 179 M 393 M 302 M 467 M 487 M 644 M 170 M 230 M 445 M -34.6 M -109 M

EBITDA per Share

-0.1 -0.27 -0.34 -0.36 -0.35 -0.28 -0.377 -0.176 -0.183 -0.192 0.00508 -0.236 -0.29 -0.537 -0.716 -1.14 - -

EV/EBITDA

-19.5 -7.3 -6.2 -7.8 -4.1 -6.3 -3.3 -5.5 -13.2 -9.6 573.8 -12.3 -17.1 -2.3 -2.4 -4.0 0.5 -

PEG

1.04 1.22 -0.27 -0.32 -0.16 0.01 0.03 -0.4 -2.74 0.0 104.65 -0.59 -0.38 -0.08 -0.08 - - -

P/B

4.7 3.7 4.5 12.8 3.2 2.0 1.8 1.0 3.9 2.5 3.4 3.7 10.9 2.1 1.6 2.1 - -

P/CF

-9.5 -4.7 -6.7 -8.0 -4.2 -6.5 -5.6 -8.6 -19.6 -16.7 -19.8 53.0 -17.7 -3.2 -3.7 -11.1 - -

ROE %

-36.97 -62.28 -74.26 -177.38 -91.85 -35.85 -50.72 -15.20 -26.89 -24.14 0.03 -27.29 -64.23 -80.42 -66.06 -57.79 -40.67 -

ROA %

-14.64 -29.40 -46.72 -74.46 -51.37 -27.93 -41.41 -14.58 -25.31 -22.68 0.03 -20.68 -56.99 -69.02 -60.52 -47.68 - -

ROCE %

-14.94 -34.37 -67.81 -121.66 -63.15 -32.08 -52.79 -17.48 -28.18 -25.04 0.53 -27.78 -62.75 -80.62 -61.85 -57.68 -40.70 -

Current Ratio

1.7 1.9 2.7 1.7 2.3 4.5 5.0 22.0 14.7 14.8 17.5 3.7 8.8 7.0 9.3 - - -

DSO

- - - - - - 636.4 399.9 149.4 28.1 12.1 304.9 160.5 101.3 209.3 - - -

All numbers in USD currency

Quarterly Financial Ratios Geron Corporation

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

- -0.02 -0.01 -0.05 -0.03 -0.02 -0.03 -0.04000000000000001 -0.04 -0.1 -0.09 -0.09 -0.08 -0.09 -0.07 - -0.1 -0.07 -0.09 - -0.08 -0.09 -0.09 -0.08000000000000002 -0.06 -0.06 -0.08 -0.15 -0.08 -0.08 -0.05 -0.04 -0.03 -0.04 -0.04 -0.05 -0.04 -0.04 -0.05 -0.05 -0.02 -0.05 -0.06 -0.05 0.17 -0.06 -0.06 -0.06 -0.06 -0.06 -0.06 -0.07 -0.06 -0.07 -0.09 -0.12 -0.13 -0.14 -0.15 -0.25 -0.16 -0.17 -0.2

EBITDA per Share

0.01 -18.4 0.44 -0.1 -0.02 -18.7 -0.02 -3.26 -0.04 -0.11 -0.09 -6.61 -0.08 -0.09 -0.07 - -0.1 -0.07 -0.09 - -0.08 -0.09 -0.09 -1.46 -0.06 -0.07 -0.08 -10.7 -0.08 -0.08 -0.06 - -0.04 -0.04 -0.05 - -0.05 -0.04 -0.05 - -0.02 -0.06 -0.06 - 0.17 -0.06 -0.06 - -0.06 -0.06 -0.06 - -0.07 -0.07 -0.09 - -0.12 -0.15 -0.15 - -0.16 -0.17 -0.2

ROE %

-21.40 -29.41 -28.09 -33.89 -30.16 -31.80 -47.46 -56.12 -68.04 -74.41 -68.94 -64.57 -81.55 -85.93 -100.31 -88.62 -106.23 -85.07 -79.10 -48.23 -59.51 -50.33 -41.05 -34.97 -45.20 -46.72 -49.76 -49.45 -32.05 -25.23 -18.60 -15.20 -18.25 -21.75 -24.02 -26.89 -26.67 -22.94 -23.83 -24.14 -23.16 -1.11 -0.64 0.03 -0.85 -27.29 -27.39 -27.29 -35.98 -42.48 -50.77 -64.23 -67.21 -72.03 -78.45 -80.42 -83.63 -78.32 -71.31 -66.06 -13.32 -14.38 -16.64

ROA %

-8.70 -12.20 -11.94 -14.78 -13.99 -16.69 -28.73 -36.70 -45.62 -50.52 -47.38 -44.86 -49.32 -50.28 -53.60 -44.62 -56.28 -50.36 -49.31 -34.14 -42.93 -38.15 -32.27 -27.55 -36.33 -38.69 -41.45 -41.48 -27.86 -21.64 -16.78 -14.58 -17.38 -20.61 -22.67 -25.31 -25.08 -21.58 -22.40 -22.68 -21.86 -0.84 -0.50 0.03 0.54 -23.27 -22.05 -20.68 -29.27 -35.99 -44.22 -56.99 -59.10 -62.83 -67.91 -69.02 -73.03 -69.24 -64.05 -60.52 -12.20 -13.18 -15.24

ROCE %

-7.03 -13.90 -15.91 -22.17 -20.58 -24.65 -42.45 -52.50 -67.52 -74.25 -69.05 -65.07 -83.02 -86.33 -98.34 -86.04 -102.98 -82.44 -76.89 -47.48 -57.18 -47.89 -39.44 -33.30 -45.44 -47.14 -50.45 -50.82 -32.80 -27.53 -20.45 -12.09 -19.07 -21.72 -24.87 -20.68 -23.85 -24.15 -25.09 -17.87 1.14 -2.36 -1.73 5.69 -1.89 -27.53 -27.54 -20.89 -35.50 -42.92 -56.35 -49.67 -68.21 -75.17 -82.25 -62.20 -75.80 -71.87 -66.91 -44.82 -13.60 -14.61 -16.61

Current Ratio

1.8 1.7 1.8 1.7 - - - 1.9 - - - 2.7 - - - 1.7 - - - 2.3 - - - 4.5 5.4 - - 5.5 5.4 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

74.0 74.2 69.4 - 69.5 63.1 77.3 - 46.6 45.2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 2622.9 48.3 - 73.5 250.1 - - - - - - - - - - - - - - - - - - -

Operating Cycle

74.0 74.2 69.4 - 69.5 63.1 68.2 - 46.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 2622.9 48.3 - 73.5 250.1 - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

74.0 74.2 69.4 - 69.5 63.1 68.2 - 46.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 2622.9 48.3 - 73.5 250.1 - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Geron Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 16.32 0.68 % $ 2.19 B canadaCanada
Cullinan Management Cullinan Management
CGEM
$ 11.37 5.28 % $ 685 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 87.46 1.86 % $ 21.1 B germanyGermany
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 24.19 -3.86 % $ 766 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 3.07 7.34 % $ 40.9 M usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.26 -0.79 % $ 57.6 M israelIsrael
AnaptysBio AnaptysBio
ANAB
$ 46.46 1.92 % $ 1.35 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 20.43 2.17 % $ 229 M usaUSA
Adagene Adagene
ADAG
$ 1.99 -1.73 % $ 117 M chinaChina
Benitec Biopharma Benitec Biopharma
BNTC
$ 9.51 10.07 % $ 443 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 20.09 1.88 % $ 3.47 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 11.55 -0.2 % $ 4.79 B irlandaIrlanda
Editas Medicine Editas Medicine
EDIT
$ 2.57 0.59 % $ 228 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 29.4 4.0 % $ 1.7 B usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 18.93 5.11 % $ 1.79 B usaUSA
Equillium Equillium
EQ
$ 1.54 15.79 % $ 88.2 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.73 4.22 % $ 98.4 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
$ 0.81 -0.12 % $ 49.7 M usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 4.18 6.78 % $ 221 M usaUSA
Ironwood Pharmaceuticals Ironwood Pharmaceuticals
IRWD
$ 4.36 8.19 % $ 706 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 21.22 -0.09 % $ 3.57 B usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
$ 0.85 11.62 % $ 551 K israelIsrael
Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc
JAZZ
$ 235.01 3.38 % $ 14.3 B irlandaIrlanda
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 2.14 5.94 % $ 18.4 M usaUSA
Liquidia Corporation Liquidia Corporation
LQDA
$ 44.53 0.08 % $ 3.83 B usaUSA
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
- -7.31 % $ 49 M usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
- - $ 1.77 B usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.59 -2.16 % $ 202 M schweizSchweiz
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 33.1 1.96 % $ 1.9 B usaUSA
Ardelyx Ardelyx
ARDX
$ 2.88 -3.85 % $ 694 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 0.39 -7.57 % $ 100 M usaUSA
Alector Alector
ALEC
$ 2.3 9.81 % $ 237 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.16 0.43 % $ 62.2 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 20.13 3.5 % $ 6.31 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 3.65 -0.54 % $ 699 M canadaCanada
Agenus Agenus
AGEN
$ 7.13 10.71 % $ 212 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 11.89 6.83 % $ 3.55 B canadaCanada
Artelo Biosciences Artelo Biosciences
ARTL
$ 1.98 -6.62 % $ 375 K usaUSA
Immatics N.V. Immatics N.V.
IMTX
$ 6.36 2.91 % $ 778 M germanyGermany
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 1.24 -2.36 % $ 391 K usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 4.14 -8.2 % $ 40.9 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.9 8.03 % $ 478 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 27.98 4.29 % $ 4.25 B usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 1.24 7.83 % $ 3.23 M usaUSA
Larimar Therapeutics Larimar Therapeutics
LRMR
$ 2.4 3.23 % $ 199 M usaUSA
Biofrontera AG Biofrontera AG
BFRA
- -8.24 % $ 105 M germanyGermany
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
- -6.97 % $ 657 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 8.97 4.3 % $ 417 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 28.5 3.04 % $ 1.33 B usaUSA
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
- 1.68 % $ 4.65 B chinaChina